

Expression of TGF- β in circulating tumor cells (CTCs) of patients with locally advanced head and neck squamous cell carcinoma (LAHNSCC) and their relation with progression free survival.

Thiago Bueno de Oliveira, Alexcia Braun, Vanessa Alves Silva, Emne Abdallah, Ulisses Ribaldo Nicolau, Daniel Garcia, Clovis Pinto, Luis Paulo Kowalski, Marcello Ferretti Fanelli, Ludmilla Thome Domingos Chinen (AC Camargo Cancer Center – São Paulo – Brasil)

Background: Currently there are different treatment options for LAHNSCC patients: upfront surgery followed by radiotherapy (RT), RT concurrent with chemotherapy (CT) or cetuximab, preceded or not by induction CT (ICT). Despite efforts, no predictive biomarkers are available to guide therapy. **Hypothesis:** The aim of this study is to determine the prognostic role of circulating tumor cells (CTCs) in LAHNSCC patients treated with a curative intent and correlate its counts, kinetics and biomarkers expression, such as TGF- β , with treatment response and survival. **Methods:** Blood samples of 47 non-metastatic LAHNSCC patients, stages III/IV, were analyzed for CTCs using the isolation by size method (ISET - Isolation by Size of Epithelial Tumor Cells, Rarecells, France®), in two scenarios: curative surgical resection and adjuvant treatment (RT+/-CT) and candidates for a non-surgical strategy (unresectable/organ-preservation) based on combination of RT with CT or cetuximab, with or without ICT. The analysis included CTCs counts, kinetics and expression of biomarkers by immunocytochemistry. **Results:** The median number of baseline CTCs was 2.6 CTCs/ml and 30 of 47 patients had CTCs analyzed after treatment, with a median count of 3.2 CTCs/ml. Patients with CTCs counts below median at baseline had a non-significant better progression free survival (PFS 12.1 x 15.2 months – p=0.20). After treatment, no difference was observed considering CTC's counts below the median (14.3 x 14.1 months – p=0.73). Expression of TGF- β in the CTCs after treatment was associated with a significant worse PFS (7.7 x 15.9 months – p<0.001) although baseline expression had a non-significant impact on survival (14 x 10 months – p=0.61). **Conclusions:** Median CTC count before treatment was associated with an impact on PFS in LAHNSCC patients treated with a curative intent, although without statistical significance. Expression of transforming growth factor beta (TGF- β), a protein involved in epithelial-mesenchymal transition, in CTCs after treatment, was strongly correlated with worse PFS in this scenario.